Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future.

@article{Sfikakis2005RituximabAT,
  title={Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future.},
  author={Petros P. Sfikakis and John N. Boletis and George C Tsokos},
  journal={Current opinion in rheumatology},
  year={2005},
  volume={17 5},
  pages={550-7}
}
PURPOSE OF REVIEW To discuss the clinical effects and the immunologic consequences of transient B-cell depletion using the anti-CD20 monoclonal antibody rituximab in systemic lupus erythematosus. RECENT FINDINGS A total of 100 rituximab-treated patients with severe disease, refractory to major immunosuppressive treatment, have been reported so far. Within a median follow-up period of 12 months rituximab was well tolerated, which is compatible with the experience accumulated from its use in… CONTINUE READING
52 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 52 extracted citations

Similar Papers

Loading similar papers…